Greater Glasgow and Clyde Medicines

Restrictions:

Restricted to specialist use in accordance with regional protocols for the following indications:

Hodgekin Lymphoma:

• Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, is restricted to specialist use in accordance with regional protocol. click here for regional protocol (NHS network access required)

Cutaneous T-cell lymphoma:

• The treatment of adults with CD30+ cutaneous T-call lymphoma (CTCL) after one prior systemic therapy is restricted to those patients with advanced CTCL, defined as mycosis fungoides stage IIB and above, primary cutaneous anaplastic large cell lymphoma or Sezary Syndrome. Click here for regional protocol (NHS network access required)

Systemic anaplastic large cell lymphoma:

• For the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma(sALCL) in combination with cyclophosphamide, doxorubicin and prednisone (CHP). Click here for regional protocol (NHS network access required)

Prescribing Notes:

The following indications are not recommended by the SMC and are non-Formulary:

• Treatment of adults with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant 
• Treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine (SMC non-submission)

BNF Link